Methicillin-Resistant Staphylococcus aureus (MRSA) - Current and Future Players

Market: Pharmaceuticals and Healthcare

Global, 125 pages report, published by GlobalData

Report ThumbnailDecember-2015
Methicillin-Resistant Staphylococcus aureus (MRSA) - Current and Future Players

Summary

GlobalData has released its pharma report, “Methicillin-Resistant Staphylococcus aureus (MRSA) - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing MRSA Market. The report identifies and analyses the key companies shaping and driving the global MRSA market. The report provides insight into the competitive MRSA landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Investigation of current and future market competition for MRSA
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of MRSA sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving MRSA market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global MRSA market landscape? Identify, understand and capitalize
  • 1.2 List of Figures
  • Figure 1: Global Sales for MRSA Therapeutics by Country, 2014 and 2024
  • Figure 2: Global Sales for MRSA Therapeutics by Region, 2014-2024
  • Figure 3: Global Sales for MRSA Therapeutics by Drug Class, 2014 and 2024
  • Figure 4: Global Sales for MRSA Therapeutics by Infection Site, 2014-2024
  • Figure 5: Global Sales for Branded MRSA Products by Company, 2014 and 2024
  • Figure 6: Company Portfolio Gap Analysis in MRSA, 2014-2024
  • 1.1 List of Tables
  • Table 1: Global Sales Forecasts ($m) for MRSA Therapeutics, 2014-2024
  • Table 2: MRSA Therapeutics Market - Global Drivers and Barriers, 2014-2024
  • Table 3: Key Companies in the MRSA Marketplace in the 7MM, 2015
  • Table 4: Pfizer’s MRSA Portfolio Assessment, 2015
  • Table 5: Merck’s MRSA Portfolio Assessment, 2015
  • Table 6: Allergan’s MRSA Portfolio Assessment, 2015
  • Table 7: The Medicines Company’s MRSA Portfolio Assessment, 2015
  • Table 8: Theravance Biopharma’s MRSA Portfolio Assessment, 2015
  • Table 9: Basilea Pharmaceutica’s MRSA Portfolio Assessment, 2015
  • Table 10: Sanofi’s MRSA Portfolio Assessment, 2015
  • Table 11: Companies with Promising Pipeline Candidates for MRSA in the 7MM, 2015
  • Table 12: Key Historical and Projected Launch Dates for MRSA Across the 7MM
  • Table 13: Key Historical and Projected Label Expansion Dates for MRSA Across the 7MM
  • Table 14: Key Historical and Projected Patent Expiry Dates for MRSA Across the 7MM
  • Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
  • 1 Table of Contents
  • 1.1 List of Tables
  • 1.2 List of Figures
  • 2 Introduction
  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Related Reports
  • 3 Market Outlook
  • 3.1 Global Markets
  • 3.1.1 Forecast
  • 3.1.2 Drivers and Barriers - Global Issues
  • 4 Current and Future Players
  • 4.1 Overview
  • 4.2 Trends in Corporate Strategy
  • 4.3 Company Profiles - Current Players
  • 4.3.1 Pfizer
  • 4.3.2 Merck
  • 4.3.3 Allergan
  • 4.3.4 The Medicines Company
  • 4.3.5 Theravance Biopharma
  • 4.3.6 Basilea Pharmaceutica
  • 4.3.7 Sanofi
  • 4.4 Additional Companies with Promising Pipeline Products
  • 4.4.1 Melinta Therapeutics
  • 4.4.2 Cempra Pharmaceuticals
  • 4.4.3 Paratek Pharmaceuticals
  • 4.4.4 Kyorin Pharmaceutical
  • 4.4.5 Nabriva Therapeutics
  • 4.4.6 Debiopharm International
  • 4.4.7 Cellceutix Corporation
  • 5 Appendix
  • 5.1 Bibliography
  • 5.2 Abbreviations
  • 5.3 Methodology
  • 5.4 Forecasting Methodology
  • 5.4.1 Hospitalized MRSA Patients
  • 5.4.2 Percentage of Drug-Treated MRSA Patients
  • 5.4.3 Drugs Included in Each Therapeutic Class
  • 5.4.4 Launch, Label Expansion, and Patent Expiry Dates
  • 5.4.5 General Pricing Assumptions
  • 5.4.6 Individual Drug Assumptions
  • 5.4.7 Generic Erosion
  • 5.4.8 Pricing of Pipeline Agents
  • 5.5 Primary Research - KOLs Interviewed for This Report
  • 5.6 Primary Research - Prescriber Survey
  • 5.7 About the Authors
  • 5.7.1 Author and Therapy Area Director
  • 5.7.2 Author
  • 5.7.3 Epidemiologist
  • 5.7.4 Global Director of Therapy Analysis and Epidemiology
  • 5.7.5 Global Head of Healthcare
  • 5.8 About GlobalData
  • 5.9 Disclaimer

Please select a license type

Share

Related Products

GlobalDataMethicillin-Resistant Staphylococcus aureus (MRSA) - Current and Future PlayersProduct ThumbnailMethicillin-Resistant Staphylococcus aureus (MRSA) - Current and Future Players, Industry ReportProduct #: 497079
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved